ERBB2 and breast carcinoma: in 2017, revealed that B cells with phenotypes CD19+, CD24+, and CD38+ were correlated with increased tumor proliferation and risk of recurrence in breast cancer subtypes ER-, PR- and HER2+ (273, 274).